undamentalytics Newsletter

Transmedics Group, Inc. insider trading

Every open-market purchase and sale by Transmedics Group, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
Transmedics Group, Inc. insider open-market trades
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Transmedics Group, Inc.’s insiders pay?

From November 13, 2019 to September 14, 2026, 17 insiders reported 6 open-market purchases and 39 sales not made under a pre-set plan in Transmedics Group, Inc. Twelve months after each purchase was reported, the shares were +52.1% against the S&P 500 on average (median +40.4%), over 4 purchases with a full year of prices; 50% beat the index. After sales, the shares moved −16.8% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on November 14, 2019 into $26,111 by November 2, 2026, +14.8% a year. It held shares 57% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $17,290 (+8.2% a year), and held throughout $27,009 (+15.4%).

$0$20.0k$40.0k$60.0k 20192020202120222023202420252026 $27.0k$26.1k$17.3k
Copying Transmedics Group, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Transmedics Group, Inc.'s insiders from November 14, 2019, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 57% of the time.
Transmedics Group, Inc.: each insider's record
InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Weill David Director 3 +40.4% (2) 50% 7 −28.3% (5) September 14, 2026
Hassanein Waleed H President & CEO 2 −54.4% (1) 0% 3 −22.5% (3) November 18, 2025
Provost Miriam VP, Global Regulatory Affairs 0 — — 5 +26.2% (5) December 15, 2023
Ranganath Anil P. See remarks 0 — — 4 −58.3% (2) March 4, 2026
Basile Edward M Director 0 — — 3 −24.3% (3) June 7, 2024
Corcoran Nicholas See remarks 0 — — 3 −37.0% (2) March 4, 2026
Gordon Stephen Chief Financial Officer 0 — — 2 −20.7% (2) May 31, 2024
Hernandez Gerardo Chief Financial Officer 0 — — 2 — March 4, 2026
Lovell Stephanie Director 0 — — 2 +3.8% (1) March 6, 2026
Tobin James R Director 0 — — 2 −32.2% (2) August 9, 2024
Abrams Capital Management, LLC 10% owner 0 — — 1 −63.8% (1) February 10, 2021
Carey John F VP of Operations 0 — — 1 −58.7% (1) March 11, 2021
Damme Laura VP, Clinical Affairs 0 — — 1 +14.2% (1) December 16, 2022
Gunderson Thomas J. Director 0 — — 1 — June 17, 2026
Kania Edwin Director 1 +182.2% (1) 100% 0 — November 30, 2021
Khayal Tamer I Chief Commercial Officer 0 — — 1 +86.6% (1) March 5, 2025
United Therapeutics Corp 10% owner 0 — — 1 −37.3% (1) December 10, 2019

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Transmedics Group, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Transmedics Group, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After 5 selling crowds, −31.1%. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
March 31, 20265 selling−46.7%−33.9%not yet
December 31, 20253 selling−13.7%−52.2%not yet
May 31, 20243 selling+16.0%−51.4%−19.3%
December 30, 20224 selling+13.9%+15.8%−3.1%
March 31, 20213 selling−28.4%−33.7%−55.0%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Transmedics Group, Inc. · Funds · Politicians